182 related articles for article (PubMed ID: 35481397)
21. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
22. Care structure of patients with mycosis fungoides and Sézary syndrome in Germany - Care research based on SHI claims data.
Assaf C; Dobos G; Zech IM; Doess A; Hibbe T; Jadasz JJ
J Dtsch Dermatol Ges; 2022 May; 20(5):643-651. PubMed ID: 35499207
[TBL] [Abstract][Full Text] [Related]
23. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
24. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.
Kuzel TM; Roenigk HH; Rosen ST
J Clin Oncol; 1991 Jul; 9(7):1298-313. PubMed ID: 2045869
[TBL] [Abstract][Full Text] [Related]
25. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
26. How I treat mycosis fungoides and Sézary syndrome.
Prince HM; Whittaker S; Hoppe RT
Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
[TBL] [Abstract][Full Text] [Related]
27. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
28. New options in diagnosis and management of mycosis fungoides and Sézary syndrome.
Enke CA
Oncology (Williston Park); 2010 May; 24(6):507-8. PubMed ID: 20568591
[No Abstract] [Full Text] [Related]
29. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.
Johnson WT; Kartan S; Sokol K; Nikbakht N; Porcu P
Leuk Lymphoma; 2021 Aug; 62(8):1877-1883. PubMed ID: 33618592
[TBL] [Abstract][Full Text] [Related]
30. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome.
Gao C; McCormack C; van der Weyden C; Goh MS; Campbell BA; Twigger R; Buelens O; Harrison SJ; Khoo C; Lade S; Prince HM
Blood; 2019 Oct; 134(16):1346-1350. PubMed ID: 31467061
[TBL] [Abstract][Full Text] [Related]
31. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
Novelli S; Martín A; Sánchez JJ; Espeso M; Mozos A; Briones J
Eur J Dermatol; 2020 Aug; 30(4):397-403. PubMed ID: 32815814
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous T-cell lymphoma (mycosis fungoides).
Lorincz AL
Lancet; 1996 Mar; 347(9005):871-6. PubMed ID: 8622396
[No Abstract] [Full Text] [Related]
33. [Item no 164: malignant lymphoma: cutaneous lymphoma].
CEDEF
Ann Dermatol Venereol; 2008 Nov; 135(11 Suppl):F160-2. PubMed ID: 18984207
[No Abstract] [Full Text] [Related]
34. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
35. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
36. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
[TBL] [Abstract][Full Text] [Related]
38. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
[TBL] [Abstract][Full Text] [Related]
39. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
